Skip to main content

Developing Novel Therapies for the Treatment of Schizophrenia, Bipolar Depression, and Other Neuropsychiatric Diseases

We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.

About us

LB-102

An oral small molecule with potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.

Learn about LB-102

Pipeline

A pipeline that leverages the broad therapeutic potential of LB-102 in schizophrenia, bipolar depression, and other neuropsychiatric diseases.

See our pipeline

Publications

Read our peer-reviewed publications and presentations.

Review our publications

Careers

Join us as we develop novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

See our open positions

Contact Us

For questions about LB-102, our pipeline, careers, and other inquiries, please reach out via the form on our Contact Us page.

Contact us